AR036554A1 - Coniosulfuros y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos - Google Patents
Coniosulfuros y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentosInfo
- Publication number
- AR036554A1 AR036554A1 ARP020103525A ARP020103525A AR036554A1 AR 036554 A1 AR036554 A1 AR 036554A1 AR P020103525 A ARP020103525 A AR P020103525A AR P020103525 A ARP020103525 A AR P020103525A AR 036554 A1 AR036554 A1 AR 036554A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- alkyl
- alkenyl
- compounds
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P11/00—Preparation of sulfur-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/001—Amines; Imines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Compuestos de la fórmula (1) que son formados por el microorganismo Coniochaeta ellipsoidea Udagawa DSM 1385, o por uno de sus mutantes o variantes, durante la fermentación y que eventualmente son sometidos a la formación de derivados. La invención se refiere también a un procedimiento para la preparación de los compuestos de la fórmula (1) y a la utilización de los mismos como medicamento. Por otra parte, se refiere a la utilización de un compuesto de fórmula (5) para la preparación de un medicamento para el tratamiento y profilaxis de las neuropatías degenerativas o de la Enfermedad de Alzheimer. Reivindicación 1: Compuestos de la fórmula (1) en la cual R1 representa 1.0 -H, o: 2.0- un radical seleccionado de entre el grupo consistente en alquilo de C1-6, C2-6-alquenilo, C2-6-alquinilo o -C6-10-arilo, que pueden estar sustituidos uno o dos veces; 2.1.-OH, 2.2 =O, 2.3 -O-(C1-6-alquilo), 2.4 -O-(C2-6-alquenilo), 2.5 -(C6-10-arilo, 2.6 -NH-C1-6-alquilo, 2.7 -NH-C2-C6-alquenilo, 2.8-NH2, o 2.9 -flúor, cloro, bromo o yodo, pudiendo los sustituyentes 2,3 a 2.8 también estar adicionalmente sustituidos por funciones -CN, amida u oxima; 3.0.- -(C1-4-alquilo)-(C6-C10-arilo), o: 4.0.- -NH2, -NH-(C1-6-alquilo), -NH-(C2-6-alquenilo), R2 representa H, metilo, etilo, n-propilo, iso-propilo, n-butilo o iso-butilo; R3 representa un radical consistente en de 1 a 10 aminoácios, que puede tener una protección N-terminal; R4 representa H, alquilo de 1 a 6 átomos de carbono, -CO-(C1-6-alquilo), y p es un número entero igual a 0, 1 o 2; con la excepción de compuestos de la fórmula (1) en los cuales simultáneamente R1 representa H, R2, representa H, R3 representa -CO-CH3, R4 representa H, y p representa 0 o 1, y/o una forma estereoisómera del compuesto de la fórmula (1) y/o mezclas de dichas formas en cualquier proporción, y/o una sal fisiológicamente aceptable del compuesto de la fórmula (1). Reivindicación 20: Utilización de un compuesto de la formula (4) para la preparación de un medicamento para el tratamiento y profilaxis de las neuropatías degenerativas o de la Enfermedad de Alzheimer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10146737A DE10146737A1 (de) | 2001-09-22 | 2001-09-22 | Coniosulfide und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
AR036554A1 true AR036554A1 (es) | 2004-09-15 |
Family
ID=7699903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020103525A AR036554A1 (es) | 2001-09-22 | 2002-09-19 | Coniosulfuros y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP1903033B1 (es) |
JP (2) | JP4287744B2 (es) |
AR (1) | AR036554A1 (es) |
AT (2) | ATE407942T1 (es) |
AU (1) | AU2002339519B2 (es) |
CA (1) | CA2461033C (es) |
DE (3) | DE10146737A1 (es) |
ES (2) | ES2314107T3 (es) |
IL (2) | IL160938A0 (es) |
MX (1) | MXPA04001951A (es) |
PE (1) | PE20030466A1 (es) |
WO (1) | WO2003029495A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010056778A1 (en) * | 2008-11-11 | 2010-05-20 | Signum Biosciences, Inc. | Isoprenyl compounds and methods thereof |
JP7318948B2 (ja) * | 2018-04-13 | 2023-08-01 | 国立大学法人京都大学 | 微生物由来化合物を用いたアルツハイマー病の予防、治療、または診断薬 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9210393D0 (en) * | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
FR2740454B1 (fr) * | 1995-10-26 | 1997-11-21 | Rhone Poulenc Rorer Sa | Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes |
EP0941319A1 (fr) * | 1996-11-08 | 1999-09-15 | Aventis Pharma S.A. | Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes |
BR0108247A (pt) * | 2000-02-10 | 2002-11-05 | Aventis Pharma Sa | Composto, polipeptìdeo, ácido nucleico, vetor, vìrus recombinante defeituoso, anticorpo ou fragmento ou derivado de anticorpo, composição farmacêutica, processos para a triagem ou a caracterização de moléculas ativas e para a produção de um composto peptìdico |
DE10060810A1 (de) | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Coniosetin und Derivate davon, Verfahren zur Herstellung und Verwendung derselben |
-
2001
- 2001-09-22 DE DE10146737A patent/DE10146737A1/de not_active Withdrawn
-
2002
- 2002-09-03 PE PE2002000837A patent/PE20030466A1/es not_active Application Discontinuation
- 2002-09-06 EP EP08000437A patent/EP1903033B1/de not_active Expired - Lifetime
- 2002-09-06 AU AU2002339519A patent/AU2002339519B2/en not_active Ceased
- 2002-09-06 IL IL16093802A patent/IL160938A0/xx unknown
- 2002-09-06 ES ES02777014T patent/ES2314107T3/es not_active Expired - Lifetime
- 2002-09-06 JP JP2003532708A patent/JP4287744B2/ja not_active Expired - Fee Related
- 2002-09-06 WO PCT/EP2002/009977 patent/WO2003029495A2/de active IP Right Grant
- 2002-09-06 AT AT02777014T patent/ATE407942T1/de not_active IP Right Cessation
- 2002-09-06 MX MXPA04001951A patent/MXPA04001951A/es active IP Right Grant
- 2002-09-06 DE DE50212774T patent/DE50212774D1/de not_active Expired - Lifetime
- 2002-09-06 ES ES08000437T patent/ES2326563T3/es not_active Expired - Lifetime
- 2002-09-06 CA CA2461033A patent/CA2461033C/en not_active Expired - Fee Related
- 2002-09-06 DE DE50213512T patent/DE50213512D1/de not_active Expired - Lifetime
- 2002-09-06 EP EP02777014A patent/EP1474440B1/de not_active Expired - Lifetime
- 2002-09-06 AT AT08000437T patent/ATE430131T1/de not_active IP Right Cessation
- 2002-09-19 AR ARP020103525A patent/AR036554A1/es not_active Application Discontinuation
-
2004
- 2004-03-18 IL IL160938A patent/IL160938A/en not_active IP Right Cessation
-
2009
- 2009-02-04 JP JP2009023173A patent/JP2009149662A/ja not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PE20030466A1 (es) | 2003-07-08 |
WO2003029495A3 (de) | 2004-02-26 |
DE50212774D1 (de) | 2008-10-23 |
JP4287744B2 (ja) | 2009-07-01 |
EP1903033A1 (de) | 2008-03-26 |
JP2009149662A (ja) | 2009-07-09 |
ES2314107T3 (es) | 2009-03-16 |
AU2002339519B2 (en) | 2007-02-08 |
EP1474440B1 (de) | 2008-09-10 |
IL160938A (en) | 2010-11-30 |
CA2461033A1 (en) | 2003-04-10 |
EP1903033B1 (de) | 2009-04-29 |
IL160938A0 (en) | 2004-08-31 |
EP1474440A2 (de) | 2004-11-10 |
ATE430131T1 (de) | 2009-05-15 |
MXPA04001951A (es) | 2004-06-07 |
CA2461033C (en) | 2011-12-06 |
DE10146737A1 (de) | 2003-04-10 |
WO2003029495A2 (de) | 2003-04-10 |
JP2005504131A (ja) | 2005-02-10 |
ES2326563T3 (es) | 2009-10-14 |
ATE407942T1 (de) | 2008-09-15 |
DE50213512D1 (de) | 2009-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU563683C (en) | Substituted acyl derivative of 1,2,3,4-tetrahydroiso- quinoline-3-carboxylic acid | |
ATE174899T1 (de) | Zytotoxische stilben-derivate und diese enthaltende pharmazeutische zusammensetzungen | |
GR3018319T3 (en) | Pyran derivatives as inhibitors of 5-lipoxygenase. | |
HUT63838A (en) | Process for producing 2-arylthiazole derivatives, pharmaceutically acdeptable salts thereof, as well as pharmaceutical compositions comprising such compounds | |
DK0412404T3 (da) | Thiazolderivater, fremgangsmåder til fremstilling deraf og farmaceutiske præparater omfattende derivaterne | |
IL124563A (en) | 5-phenyl-3-(substituted oximino) pyrrolo [3, 2-h] isoquinoline-2-one derivatives pharmaceutical compositions containing them and their preparation | |
DK162883D0 (da) | N-glucosylerede carboxylsyreamidderivater, fremgangsmade til fremstilling heraf samt deres anvendelse til pavirkning af organismens egen forsvarsmekanisme | |
DE60141520D1 (de) | 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten | |
NO940523D0 (no) | Nye pyrazin-derivater | |
SE8107273L (sv) | 2-oxoazetidinderivat, sett att framstella democh anvendning derav | |
NO307464B1 (no) | Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter | |
ES8404361A1 (es) | Un procedimiento para la preparacion de un derivado de cefalosporina. | |
AR036554A1 (es) | Coniosulfuros y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos | |
ATE212637T1 (de) | Anitbiotisch wirksame cephalosporine und verfahren zu ihrer herstellung | |
JPS5455047A (en) | Vinyl chloride resin composition | |
GB1473981A (en) | Hydrazino-cephalosporanic acid derivatives | |
EP0802179A4 (en) | DERIVATE SUBSTITUTED AMIDINONAPHTHYLESTER | |
FR2242986B1 (es) | ||
ES2092470T3 (es) | Derivados de pirrolidina. | |
BRPI0411057A (pt) | análogos de prostaglandina e de piperidinila | |
SE8403168L (sv) | Karboxylsyraamidforeningar och derivat derav | |
ES2052058T3 (es) | Composiciones agricolas y horticolas que confieren resistencia a las plantas contra las tensiones producidas por la sal y el agua. | |
FI922518A (fi) | Menetelmä farmaseuttisesti käyttökelpoisten pilokarpiinijohdannaisten valmistamiseksi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |